The objectives of partial nephrectomy (PN) for kidney cancer are to optimize cancer control by obtaining negative margins while preserving as much renal function as possible.
The renal function preservation clinic for patients with kidney cancer represents a new multidisciplinary approach to an old problem.
Recent therapeutic advances in metastatic renal cell carcinoma (RCC) have included agents targeted against vascular endothelial growth factor (VEGF).
Protection of renal function is a primary concern of physicians who manage surgical or medical diseases of the kidney, such as renal tumors, urinary calculi, renal vascular disease, or ureteropelvic junction obstruction.
The medication is being tested as adjuvant therapy in patients with locally advanced urothelial cancer.
